Relapsed or refractory extracranial solid tumors in children and adolescents.
Conditions
Brief summary
Dose confirmation phase: Rate of dose-limiting toxicities.
Detailed description
Expansion phase: Rate of objective responses (complete and partial responses) of the combination., Feasibility of the combination: rate of patients who meet selection criteria who can receive at least one cycle of the combination of Alo-Celyvir with chemo-radiotherapy and measurement of the time from recruitment to the preparation and administration of Alo-Celyvir., Dose confirmation phase: Rate of objective responses (complete and partial responses) of the combination., Progression free survival., Global survival., Rate of adverse events.
Interventions
DRUGAloCelyvir
Sponsors
Fundacion Para La Investigacion Biomedica Hospital Infantil Universitario Nino Jesus
Eligibility
Sex/Gender
All
Age
0 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dose confirmation phase: Rate of dose-limiting toxicities. | — |
Secondary
| Measure | Time frame |
|---|---|
| Expansion phase: Rate of objective responses (complete and partial responses) of the combination., Feasibility of the combination: rate of patients who meet selection criteria who can receive at least one cycle of the combination of Alo-Celyvir with chemo-radiotherapy and measurement of the time from recruitment to the preparation and administration of Alo-Celyvir., Dose confirmation phase: Rate of objective responses (complete and partial responses) of the combination., Progression free survival., Global survival., Rate of adverse events. | — |
Countries
Spain
Outcome results
None listed